The first Research Institute of China University of science and technology will focus on the research, development and industrialization of peptide drugs

(reprinted on guangming.com) the development prospect of biomedical industry is good, and drug research and development is a key link in the industrial chain Recently, the first peptide drug seminar of advanced technology research institute of China University of science and technology was held in our city, which was sponsored by the first Research Institute of China University of science and technology and organized by the protein and peptide drug laboratory of the first Research Institute of China University of science and technology The reporter learned that in the future, the Institute will focus on peptide drug research and development and industrialization, and actively promote internationally renowned pharmaceutical enterprises to develop the biomedical industry in Anhui and Hefei What is "polypeptide" and "polypeptide drug"? According to the introduction, polypeptide generally refers to a compound composed of less than 100 amino acids connected by peptide bond, and its relative molecular weight is less than 10000 Peptide drug is one of the most important innovative biological drugs At present, most of the common western medicines on the market are small molecule chemicals Compared with small molecule chemical drugs, peptide drugs are superior to small molecule chemical drugs in biological activity, specificity and solving complex diseases Compared with protein drugs, peptide drugs have better stability, higher purity and lower cost The quality control level of peptide drugs is close to that of small molecule chemicals, and the activity is close to that of protein drugs It has the characteristics of high activity, low dose and low toxicity Combining the advantages of the two, it is suitable for solving complex diseases that are difficult to be solved by small molecule chemicals It is mainly aimed at the unmet medical needs such as infection, tumor and metabolic diseases, and widely used in endocrine system Immune system, digestive system, cardiovascular system, blood system, musculoskeletal system, etc In other words, with the development of medicine and biochemical technology, peptide drugs have become an important diagnosis, monitoring, prevention and treatment drugs In recent years, peptide as a therapeutic drug has attracted more and more attention At present, nearly 60 peptide products have been approved for marketing in the world The global market share of peptide drugs in 2015 was about 19.6 billion US dollars, maintaining a high growth rate of about 10% Among them, the innovative peptide drug market is about US $10.2 billion In China, 14 peptide preparations have been sold on the market, 4 of which are all imported, and 10 belong to generic drugs or dosage forms At present, the development of biopeptide drugs in our province is relatively backward, and has not yet formed industrial driving role and industrial agglomeration, so we need to further increase investment to attract high-level R & D talents and well-known enterprises According to Tian Changlin, professor and doctoral director of College of life sciences, University of science and technology of China, and director of protein and polypeptide medicine laboratory, Institute of advanced technology, University of science and technology of China, the laboratory mainly develops polypeptide drugs with important market significance for analgesia, immune diseases and other diseases, and actively helps our province to introduce internationally renowned pharmaceutical enterprises to develop regional biological medicine industry It is worth noting that during the conference, a number of well-known pharmaceutical companies around the world expressed their intention to strengthen exchanges and R & D cooperation.